


FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/725,952		ATTY. DOCKET NO.: I0248.70015US01	
				FILING DATE: December 1, 2003		CONFIRMATION NO.: 3968	
				APPLICANT: Bachovchin et al.			
				GROUP ART UNIT: 1631		EXAMINER: Not Yet Assigned	
Sheet	1	of	1				



U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code		

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No.	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)	
MB	*C129	Darmoul et al., Dipeptidyl peptidase IV (CD 26) gene expression in enterocyte-like colon cancer cell lines HT-29 and Caco-2. Cloning of the complete human coding sequence and changes of dipeptidyl peptidase IV mRNA levels during cell differentiation. J Biol Chem. 1992 Mar 5; 267(7):4824-33.		
MB	*C130	Reinhold et al., Inhibitors of dipeptidyl peptidase IV (DP IV, CD26) specifically suppress proliferation and modulate cytokine production of strongly CD26 expressing U937 cells. Immunobiology. 1994 Dec;192(1-2):121-36.		

EXAMINER:	DATE CONSIDERED:
-----------	------------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 09/812,528, filed March 20, 2001, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - The Office hereby waives the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b). For all patent applications filed on or before June 30, 2003, copies of cited U.S. patents and patent application publications are still required unless an eIDS is filed. Copies of all other patent(s), publication(s), or other information listed must still be provided, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICATION NO.: 10/725,952	ATTY. DOCKET NO.: 10248.70015US01
		FILING DATE: December 1, 2003	CONFIRMATION NO.: 3968
		APPLICANT: Bachovchin et al.	
		GROUP ART UNIT: 1631	EXAMINER: Not Yet Assigned
Sheet	1	of	10

U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
MM	*A1	4,318,904		Shaw et al.	03-09-1982
	*A2	4,443,609		Qude Alink et al.	04-17-1984
	*A3	4,499,082		Shenvi et al.	02-12-1985
	*A4	4,582,821		Kettner et al.	04-15-1986
	*A5	4,636,492		Kettner et al.	01-13-1987
	*A6	4,644,055		Kettner et al.	02-17-1987
	*A7	4,652,552		Kettner et al.	03-24-1987
	*A8	4,935,493		Bachovchin et al.	06-19-1990
	*A9	4,963,655		Kinder et al.	10-16-1990
	*A10	5,093,477		Mölling et al.	03-03-1992
	*A11	5,187,157		Kettner et al.	02-16-1993
	*A12	5,215,926		Etchells et al.	06-01-1993
	*A13	5,242,904		Kettner et al.	09-07-1993
	*A14	5,250,720		Kettner et al.	10-05-1993
	*A15	5,288,707		Metternich	02-22-1994
	*A16	5,296,604		Hanko et al.	03-22-1994
	*A17	5,329,028		Ashkenzi et al.	07-12-1994
	*A18	5,378,624		Berenson et al.	01-03-1995
	*A19	5,384,410		Kettner et al.	01-24-1995
	*A20	5,444,049		de Nanteuil et al.	08-22-1995
	*A21	5,462,928		Bachovchin et al.	10-31-1995
	*A22	5,506,130		Peterson et al.	04-09-1996
	*A23	5,527,923		Klingler et al.	06-18-1996
	*A24	5,543,396		Powers et al.	08-06-1996
	*A25	5,554,728		Basava et al.	09-10-1996
	*A26	5,635,386		Palsson et al.	06-03-1997
	*A27	5,635,387		Fei et al.	06-03-1997
	*A28	5,646,043		Emerson et al.	07-08-1997
	*A29	6,258,597	B1	Bachovchin et al.	07-10-2001
	A30	4,999,082		Krenner et al.	03-12-1991
	A31	5,965,532		Bachovchin	10-12-1999
	A32	6,040,145		Huber et al.	03-21-2000
	A33	6,100,234		Huber et al.	08-08-2000
	A34	6,300,314	B1	Wallner et al.	10-09-2001
	A35	6,355,614	B1	Wallner	03-12-2002
	A36	6,503,882	B2	Huber et al.	01-07-2003
	A37	6,692,753	B2	Huber et al.	02-17-2004
	A38	6,703,238	B2	Bachovchin et al.	03-09-2004
	A39	6,770,628	B2	Wallner et al.	08-03-2004

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/725,952		ATTY. DOCKET NO.: 10248.70015US01	
				FILING DATE: December 1, 2003		CONFIRMATION NO.: 3968	
				APPLICANT: Bachovchin et al.			
				GROUP ART UNIT: 1631		EXAMINER: Not Yet Assigned	
Sheet	2	of	10				

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
<i>MM</i>	A40	6,825,169	B1	Bachovchin et al.	11-30-2004
	A41	2003-0158114	A1	Wallner et al.	08-21-2003
	A42	2003-0212044	A1	Huber et al.	11-13-2003
	A43	2004-0077601	A1	Adams et al.	04-22-2004
<i>MM</i>	A44	2005-0037976	A1	Wallner et al.	02-17-2005

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			
<i>MM</i>	*B1	DD	158109		Martin-Luther-Universitaet Halle Wittenberg	12-29-1982	Y-Abstract Only
	*B2	DD	270382	A1	Martin-Luther-Universitaet Halle Wittenberg	07-26-1989	Y-Abstract Only
	*B3	DD	296075	A5	Martin-Luther-Universitaet Halle Wittenberg	11-21-1991	Y-Abstract Only
	*B4	EP	0 356 223	A2	Merck and Co., Inc.	02-26-1990	
	*B5	EP	0 371 467	A2	Hoechst Aktiengesellschaft	06-06-1990	
	*B6	EP	0 420 913	A1	Cell Med, Inc.	12-28-1989	
	*B7	EP	0 471 651	A2	Sandoz Ltd.	02-19-1992	
	*B8	EP	0 481 311	A2	Merck Patent Gesellschaft	10-18-1990	
	*B9	EP	0 615 978	A1	Adir et Compagnie	09-21-1994	
	*B10	EP	0 688 788	A1	Adir et Compagnie	06-22-1994	
	*B11	WO	89/03223	A1	Bachovchin et al.	04-20-1989	
	*B12	WO	91/16339	A1	New England Medical Center Hospitals, Inc.	10-31-1991	
	*B13	WO	91/17767	A1	New England Medical Center Hospitals, Inc.	11-28-1991	
	*B14	WO	92/12140	A1	Georgia Tech Research Corporation	07-23-1992	
	*B15	WO	92/17490	A1	The Upjohn Company	10-15-1992	
	*B16	WO	93/02057	A1	Smith-Kline Beecham Corporation	02-04-1993	
	*B17	WO	93/05011	A1	Sandoz Ltd.	03-18-1993	
	*B18	WO	93/08259	A2	New England Medical Center Hospitals, Inc.	04-29-1993	
	*B19	WO	93/10127	A1	Boehringer Ingelheim Pharmaceuticals, Inc.	05-27-1993	
	*B20	WO	93/16102	A1	Dana-Farber Cancer Institute	08-19-1993	
	*B21	WO	94/03055	A1	The Government of the United States of America	02-17-1994	
<i>MM</i>	*B22	WO	94/09132	A1	Dana-Farber Cancer Institute	04-28-1994	

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/725,952		ATTY. DOCKET NO.: 10248.70015US01	
				FILING DATE: December 1, 2003		CONFIRMATION NO.: 3968	
				APPLICANT: Bachovchin et al.			
				GROUP ART UNIT: 1631		EXAMINER: Not Yet Assigned	
Sheet	3	of	10				

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			
<i>mm</i>	*B23	WO	94/20526	A1	Sandoz-Erfindungen Verwaltungsgesellschaft M.B.H.	09-15-1994	
	*B24	WO	94/25873	A1	Hall	11-10-1994	
	*B25	WO	94/28915	A1	Institut Pasteur	12-22-1994	
	*B26	WO	94/29335	A1	Astra Aktiebolag	12-22-1994	
	*B27	WO	95/11689	A1	Trustees of Tufts College	05-04-1995	
	*B28	WO	95/15309	A1	Ferring B.V.	06-08-1995	
	*B29	WO	95/12618	A1	Eurogenetics N.V.	05-11-1995	
	*B30	WO	95/29190	A1	Institut Pasteur	11-02-1995	
	*B31	WO	95/29691	A1	Georgia Tech Research Corporation	11-09-1995	
	*B32	WO	95/34538	A2	Univeristaire Instelling Antwerpen	12-21-1995	
	*B33	WO	96/40263	A2	Cellpro, Incorporated	12-19-1996	
	*B34	WO	96/40858	A1	Aastrom Biosciences Inc.	12-19-1996	
	*B35	WO	98/00439	A2	Trustees of Tufts College	01-08-1998	
	*B36	WO	98/50046	A1	Trustees of Tufts College	11-12-1998	
	*B37	WO	98/50066	A1	Trustees of Tufts College	11-12-1998	
	*B38	WO	99/16864	A1	Point Therapeutics, Inc.	04-08-1999	
	B39	WO	99/56753	A1	Point Therapeutics, Inc.	11-11-1999	
	B40	WO	99/62914	A1	Point Therapeutics, Inc.	12-09-1999	
	B41	WO	00/10549	A1	Point Therapeutics, Inc.	03-02-2000	
	B42	WO	00/71135	A1	Point Therapeutics, Inc.	11-30-2000	
	B43	WO	2004/004658	A2	Point Therapeutics, Inc.	01-15-2004	
<i>mm</i>	B44	WO	2004/004661	A2	Point Therapeutics, Inc.	01-15-2004	

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
<i>mm</i>	*C1	[No Author Listed] Perstorp Biotech Company, Molecular Biology Catalog. 1994.	
	*C2	AGUILA et al., From stem cells to lymphocytes: biology and transplantation. Immunol Rev. 1997 Jun;157:13-40.	
	*C3	ANSORGE et al., CD26/dipeptidyl peptidase IV in lymphocyte growth regulation. Adv Exp Med Biol. 1997;421:127-40.	
	*C4	AUSTIN et al., Proximity versus allostery: the role of regulated protein dimerization in biology. Chem Biol. 1994 Nov;1(3):131-6.	
	*C5	BACHOVCHIN et al., Inhibition of IgA1 proteinases from Neisseria gonorrhoeae and Hemophilus influenzae by peptide prolyl boronic acids. J Biol Chem. 1990 Mar 5;265(7):3738-43.	
	*C6	BAILEY et al., An introduction to peptide chemistry. 1990; 1-81.	
	*C7	BARTON et al., Binding of the T cell activation monoclonal antibody Ta1 to dipeptidyl peptidase IV. J Leukoc Biol. 1990 Oct;48(4):291-6. Abstract Only.	
<i>mm</i>	*C8	BAUGH et al., Role and potential therapeutic value of proteinase inhibitors in tissue destruction. in Proteinases and Tumor Invasion. Sträuli et al., editors. Raven Press, New York, 1980. p157-180.	

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/725,952		ATTY. DOCKET NO.: 10248.70015US01	
				FILING DATE: December 1, 2003		CONFIRMATION NO.: 3968	
				APPLICANT: Bachovchin et al.			
				GROUP ART UNIT: 1631		EXAMINER: Not Yet Assigned	
Sheet	4	of	10				

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
<i>mm</i>	*C9	BLUMENSTEIN et al., Synthetic non-peptide inhibitors of HIV protease. Biochem Biophys Res Commun. 1989 Sep 15;163(2):980-7.	
	*C10	BODANSZKY et al., Principles of peptide synthesis. 1984: 16.	
	*C11	BODANSZKY et al., The practice of peptide synthesis. 1984: 21.	
	*C12	BODANSKY et al., Peptide Chemistry, A practical textbook. 1988: Springer-Verlag. p1-9.	
	*C13	BOROS et al., Fluoroolefin peptide isosteres: tools for controlling peptide conformations. Tetrahedron Lett. 1994;35:6033-6.	
	*C14	BRADY et al., Drug design. Reflections on a peptide. Nature. 1994 Apr 21;368(6473):692-3.	
	*C15	BRANDER et al., Heterogeneous T cell responses to beta-lactam-modified self-structures are observed in penicillin-allergic individuals. J Immunol. 1995 Sep 1;155(5):2670-8. Abstract Only.	
	*C16	BRISTOL et al., Characterization of a novel rat thymocyte costimulating antigen by the monoclonal antibody 1.3. J Immunol. 1992 Jan 15;148(2):332-8. Abstract Only.	
	*C17	BRISTOL et al., Thymocyte costimulating antigen is CD26 (dipeptidyl-peptidase IV). Costimulation of granulocyte, macrophage, and T lineage cell proliferation via CD26. J Immunol. 1992 Jul 15;149(2):367-72. Abstract Only.	
	*C18	BRISTOL et al., Inhibition of CD26 enzyme activity with pro-boropro stimulates rat granulocyte/macrophage colony formation and thymocyte proliferation in vitro. Blood. 1995 Jun 15;85(12):3602-9.	
	*C19	BUNGY et al., Mapping of T cell epitopes of the major fraction of rye grass using peripheral blood mononuclear cells from atopics and non-atopics. II. Isoallergen clone 5A of Lolium perenne group I (Lol p I). Eur J Immunol. 1994 Sep;24(9):2098-103. Abstract Only.	
	*C20	CHAN et al., 32 cases of sympathetic ophthalmia. A retrospective study at the National Eye Institute, Bethesda, Md., from 1982 to 1992. Arch Ophthalmol. 1995 May;113(5):597-600. Abstract Only.	
	*C21	CHAZENBALK et al., Human organ-specific autoimmune disease. Molecular cloning and expression of an autoantibody gene repertoire for a major autoantigen reveals an antigenic immunodominant region and restricted immunoglobulin gene usage in the target organ. J Clin Invest. 1993 Jul;92(1):62-74. Abstract Only.	
	*C22	COLOWICK et al., Methods in Enzymology. 220-5.	
	*C23	CORDES et al., Transition states for hydrolysis of acetals, ketals glycosides, and glycosylamines. Chapter 11. 429-65.	
	*C24	COUTTS et al., Structure-activity relationships of boronic acid inhibitors of dipeptidyl peptidase IV. 1. Variation of the P2 position of Xaa-boroPro dipeptides. J Med Chem. 1996 May 10;39(10):2087-94.	
	*C25	DANG et al., Cell surface modulation of CD26 by anti-1F7 monoclonal antibody. Analysis of surface expression and human T cell activation. J Immunol. 1990 Dec 15;145(12):3963-71. Abstract Only.	
	*C26	DARCY et al., Protection of mice and nude rats against toxoplasmosis by a multiple antigenic peptide construction derived from Toxoplasma gondii P30 antigen. J Immunol. 1992 Dec 1;149(11):3636-41. Abstract Only.	
<i>mm</i>	*C27	DAW et al., Glutamic acid decarboxylase autoantibodies in stiff-man syndrome and insulin-dependent diabetes mellitus exhibit similarities and differences in epitope recognition. J Immunol. 1996 Jan 15;156(2):818-25. Abstract Only.	

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/725,952		ATTY. DOCKET NO.: 10248.70015US01	
				FILING DATE: December 1, 2003		CONFIRMATION NO.: 3968	
				APPLICANT: Bachovchin et al.			
				GROUP ART UNIT: 1631		EXAMINER: Not Yet Assigned	
Sheet	5	of	10				

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
mm	*C28	DE CAESTECKER et al., The detection of intracytoplasmic interleukin-1 alpha, interleukin-1 beta and tumour necrosis factor alpha expression in human monocytes using two colour immunofluorescence flow cytometry. J Immunol Methods. 1992 Sep 18;154(1):11-20. Abstract Only.	
	*C29	DEMUTH et al., Design of (omega-N-(O-acyl)hydroxy amid) aminodicarboxylic acid pyrrolidides as potent inhibitors of proline-specific peptidases. FEBS Lett. 1993 Mar 29;320(1):23-7.	
	*C30	DUDLER et al., Carbohydrate-dependent, HLA class II-restricted, human T cell response to the bee venom allergen phospholipase A2 in allergic patients. Eur J Immunol. 1995 Feb;25(2):538-42. Abstract Only.	
	*C31	DUKE-COHAN et al., Targeting of an activated T-cell subset using a bispecific antibody-toxin conjugate directed against CD4 and CD26. Blood. 1993 Oct 1;82(7):2224-34. Abstract Only.	
	*C32	DUPONT et al., Immunology of hematopoietic stem cell transplantation: a brief review of its history. Immunol Rev. 1997 Jun;157:5-12.	
	*C33	EBENBICHLER et al., Structure-function relationships of the HIV-1 envelope V3 loop tropism determinant: evidence for two distinct conformations. AIDS. 1993 May;7(5):639-46. Abstract Only.	
	*C34	EL FAR et al., Antigens associated with N- and L-type calcium channels in Lambert-Eaton myasthenic syndrome. J Neurochem. 1995 Apr;64(4):1696-702. Abstract Only.	
	*C35	FAUCI et al., The human immunodeficiency virus: infectivity and mechanisms of pathogenesis. Science. 1988 Feb 5;239(4840):617-22. Review. Abstract Only.	
	*C36	FLEISHER et al., Triggering of cytotoxic T lymphocytes and NK cells via the Tp103 pathway is dependent on the expression of the T cell receptor/CD3 complex. J Immunol. 1988 Aug 15;141(4):1103-7. Abstract Only.	
	*C37	FLENTKE et al., Inhibition of dipeptidyl aminopeptidase IV (DP-IV) by Xaa-boroPro dipeptides and use of these inhibitors to examine the role of DP-IV in T-cell function. Proc Natl Acad Sci U S A. 1991 Feb 15;88(4):1556-9.	
	*C38	FREEMAN et al., T and B cell reactivity to adrenal antigens in autoimmune Addison's disease. Clin Exp Immunol. 1992 May;88(2):275-9. Abstract Only.	
	*C39	GOODMAN et al., On the concept of linear modified retro-peptide structures. Acc Chem Res. 1979;12(1):1-7.	
	*C40	GOODSTONE et al., Cellular immunity to cartilage aggrecan core protein in patients with rheumatoid arthritis and non-arthritic controls. Ann Rheum Dis. 1996 Jan;55(1):40-6. Abstract Only.	
	*C41	GUICHARD et al., Partially modified retro-inverso pseudopeptides as non-natural ligands for the human class I histocompatibility molecule HLA-A2. J Med Chem. 1996 May 10;39(10):2030-9.	
	*C42	GÜNTHER et al., Solution structures of the DP IV (CD26) inhibitor Val-BoroPro determined by NMR spectroscopy. Magn Reson Chem. 1995;33:959-70.	
	*C43	GUTHEIL et al., Separation of L-Pro-DL-boroPro into its component diastereomers and kinetic analysis of their inhibition of dipeptidyl peptidase IV. A new method for the analysis of slow, tight-binding inhibition. Biochemistry. 1993 Aug 31;32(34):8723-31.	
	*C44	HALL et al., Immunogenetics of dermatitis herpetiformis. Semin Dermatol. 1991 Sep;10(3):240-5. Abstract Only.	
	*C45	HART et al., Design of experimental synthetic peptide immunogens for prevention of HIV-1 and HTLV-I retroviral infections. Pharm Biotechnol. 1995;6:821-45. Abstract Only.	
	*C46	HEGEN et al., Enzymatic activity of CD26 (dipeptidylpeptidase IV) is not required for its signalling function in T cells. Immunobiology. 1993 Dec;189(5):483-93.	
mm	*C47	HEGEN et al., The T cell triggering molecule Tp103 is associated with dipeptidyl aminopeptidase IV activity. J Immunol. 1990 Apr 15;144(8):2908-14. Abstract Only. (previously cited as p2980)	

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/725,952		ATTY. DOCKET NO.: 10248.70015US01	
				FILING DATE: December 1, 2003		CONFIRMATION NO.: 3968	
				APPLICANT: Bachovchin et al.			
				GROUP ART UNIT: 1631		EXAMINER: Not Yet Assigned	
Sheet	6	of	10				

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
<i>mm</i>	*C48	HEGEN et al., Function of dipeptidyl peptidase IV (CD26, Tp103) in transfected human T cells. Cell Immunol. 1993 Feb;146(2):249-60. Abstract Only.	
	*C49	HEINS et al., Mechanism of proline-specific proteinases: (I) Substrate specificity of dipeptidyl peptidase IV from pig kidney and proline-specific endopeptidase from Flavobacterium meningosepticum. Biochim Biophys Acta. 1988 May 18;954(2):161-9. Abstract Only.	
	*C50	IKAGAWA et al., Single amino acid substitutions on a Japanese cedar pollen allergen (Cry j 1)-derived peptide induced alterations in human T cell responses and T cell receptor antagonism. J Allergy Clin Immunol. 1996 Jan;97(1 Pt 1):53-64. Abstract Only.	
	*C51	JAMES et al., Peptide autoantigenicity of the small nuclear ribonucleoprotein C. Clin Exp Rheumatol. 1995 May-Jun;13(3):299-305. Abstract Only.	
	*C52	JAMESON et al., A rationally designed CD4 analogue inhibits experimental allergic encephalomyelitis. Nature. 1994 Apr 21;368(6473):744-6.	
	*C53	JANEWAY et al., Immunobiology: The immune system in health and disease. Current Biology LTD. 1994; Ch12: 1-35.	
	*C54	JARDETZKY et al., Three-dimensional structure of a human class II histocompatibility molecule complexed with superantigen. Nature. 1994 Apr 21;368(6473):711-8.	
	*C55	JIANG et al., Inhibition of human immunodeficiency virus type 1 infection in a T-cell line (CEM) by new dipeptidyl-peptidase IV (CD26) inhibitors. Res Virol. 1997 Jul-Aug;148(4):255-66.	
	*C56	JORGENSEN et al., Molecular components of T-cell recognition. Annu Rev Immunol. 1992;10:835-73. Abstract Only.	
	*C57	KAHNE et al., Enzymatic activity of DPPIV/CD26 is involved in PMA-induced hyperphosphorylation of p56lck. Immunol Lett. 1995 May;46(1-2):189-93.	
	*C58	KALLURI et al., Identification of the alpha 3 chain of type IV collagen as the common autoantigen in ant basement membrane disease and Goodpasture syndrome. J Am Soc Nephrol. 1995 Oct;6(4):1178-85.	
	*C59	KAMEOKA et al., Direct association of adenosine deaminase with a T cell activation antigen, CD26. Science. 1993 Jul 23;261(5120):466-9. Abstract Only.	
	*C60	KAMEOKA et al., Differential CD26-mediated activation of the CD3 and CD2 pathways after CD6-depleted allogeneic bone marrow transplantation. Blood. 1995 Feb 15;85(4):1132-7. Abstract Only.	
	*C61	KARGES et al., Self and non-self antigen in diabetic autoimmunity: molecules and mechanisms. Mol Aspects Med. 1995;16(2):79-213. Abstract Only.	
	*C62	KELLY et al., Immunosuppressive boronic acid dipeptides: correlation between conformation and activity. J Am Chem Soc. 1993;115:12637-8.	
	*C63	KELLY et al., The efficient synthesis and simple resolution of a proline boronate ester suitable for enzyme inhibition studies. Tetrahedron. 1993;49:1009-16. Abstract Only.	
	*C64	KETTNER et al., Kinetic properties of the binding of alpha-lytic protease to peptide boronic acids. Biochemistry. 1988 Oct 4;27(20):7682-8.	
	*C65	KETTNER et al., Peptide boronic acid inhibitors of trypsin-like proteases, their preparation and use as anticoagulants and inflammation inhibitors. Chemical Abstracts. 1990;112:80. Abstract number 91790c.	
<i>mm</i>	*C66	KINDER et al., Analogues of carbamyl aspartate as inhibitors of dihydroorotase: preparation of boronic acid transition-state analogues and a zinc chelator carbamylhomocysteine. J Med Chem. 1990 Feb;33(2):819-23.	

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/725,952		ATTY. DOCKET NO.: I0248.70015US01	
				FILING DATE: December 1, 2003		CONFIRMATION NO.: 3968	
				APPLICANT: Bachovchin et al.			
				GROUP ART UNIT: 1631		EXAMINER: Not Yet Assigned	
Sheet	7	of	10				

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
<i>My</i>	*C67	KOKAWA et al., Detection of platelet antigen for antiplatelet antibodies in idiopathic thrombocytopenic purpura by flow cytometry, antigen-capture ELISA, and immunoblotting: a comparative study. Eur J Haematol. 1993 Feb;50(2):74-80. Abstract Only.	
	*C68	KUBOTA et al., Involvement of dipeptidyl peptidase IV in an in vivo immune response. Clin Exp Immunol. 1992 Aug;89(2):192-7.	
	*C69	KUBOTA et al., Dipeptidyl peptidase IV (DP IV) activity in serum and on lymphocytes of MRL/Mp-lpr/lpr mice correlates with disease onset. Clin Exp Immunol. 1994 May;96(2):292-6.	
	*C70	KUCHROO et al., Induction of experimental allergic encephalomyelitis by myelin proteolipid-protein-specific T cell clones and synthetic peptides. Pathobiology. 1991;59(5):305-12. Abstract Only.	
	*C71	KUCHROO et al., T-cell receptor alpha chain plays a critical role in antigen-specific suppressor cell function. Proc Natl Acad Sci U S A. 1991 Oct 1;88(19):8700-4. Abstract Only.	
	*C72	KUCHROO et al., Experimental allergic encephalomyelitis mediated by cloned T cells specific for a synthetic peptide of myelin proteolipid protein. Fine specificity and T cell receptor V beta usage. J Immunol. 1992 Jun 15;148(12):3776-82. Abstract Only.	
	*C73	KUCHROO et al., Cytokines and adhesion molecules contribute to the ability of myelin proteolipid protein-specific T cell clones to mediate experimental allergic encephalomyelitis. J Immunol. 1993 Oct 15;151(8):4371-82. Abstract Only.	
	*C74	KUCHROO et al., T cell receptor (TCR) usage determines disease susceptibility in experimental autoimmune encephalomyelitis: studies with TCR V beta 8.2 transgenic mice. J Exp Med. 1994 May 1;179(5):1659-64. Abstract Only.	
	*C75	KUCHROO et al., A single TCR antagonist peptide inhibits experimental allergic encephalomyelitis mediated by a diverse T cell repertoire. J Immunol. 1994 Oct 1;153(7):3326-36. Abstract Only.	
	*C76	LININGTON et al., Cell adhesion molecules of the immunoglobulin supergene family as tissue-specific autoantigens: induction of experimental allergic neuritis (EAN) by P0 protein-specific T cell lines. Eur J Immunol. 1992 Jul;22(7):1813-7. Abstract only.	
	*C77	LINSLEY et al., Effects of anti-gp120 monoclonal antibodies on CD4 receptor binding by the env protein of human immunodeficiency virus type 1. J Virol. 1988 Oct;62(10):3695-702. Abstract Only.	
	*C78	LIU et al., Molecular mapping of a pathogenically relevant BP180 epitope associated with experimentally induced murine bullous pemphigoid. J Immunol. 1995 Dec 1;155(11):5449-54. Abstract Only.	
	*C79	LOPEZ et al., Characterization of SPf(66)n: a chimeric molecule used as a malaria vaccine. Vaccine. 1994 May;12(7):585-91. Abstract Only.	
	*C80	LOTZOVA et al., Genesis of human oncolytic natural killer cells from primitive CD34+CD33-bone marrow progenitors. J Immunol. 1993 Jun 15;150(12):5263-9.	
	*C81	LUFTIG et al., Update on Viral Pathogenesis: recent work on three human pathogens illustrates the paths being taken in viral pathogenesis research. ASM News. 1990;56(7):366-8.	
	*C82	MARGUET et al., cDNA cloning for mouse thymocyte-activating molecule. A multifunctional ecto-dipeptidyl peptidase IV (CD26) included in a subgroup of serine proteases. J Biol Chem. 1992 Feb 5;267(4):2200-8. Abstract Only. (previously cited as Darmoul et al.)	
	*C83	MATTESON et al., Synthesis and properties of pinanediol .alpha.-amido boronic esters. Organometallics. 1984;3(8):1284-8.	
<i>mm</i>	*C84	MITTRUCKER et al., The cytoplasmic tail of the T cell receptor zeta chain is required for signaling via CD26. Eur J Immunol. 1995 Jan;25(1):295-7. Abstract Only.	

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/725,952		ATTY. DOCKET NO.: 10248.70015US01	
				FILING DATE: December 1, 2003		CONFIRMATION NO.: 3968	
				APPLICANT: Bachovchin et al.			
				GROUP ART UNIT: 1631		EXAMINER: Not Yet Assigned	
Sheet	8	of	10				

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
MJB	*C85	MORIMOTO et al., 1F7, a novel cell surface molecule, involved in helper function of CD4 cells. J Immunol. 1989 Dec 1;143(11):3430-9. Erratum in: J Immunol 1990 Mar 1;144(5):2027. Abstract Only.	
	*C86	MOSMANN et al., Cytokine patterns during the progression to AIDS. Science. 1994 Jul 8;265(5169):193-4.	
	*C87	MULLINS et al., Identification of thyroid stimulating hormone receptor-specific T cells in Graves' disease thyroid using autoantigen-transfected Epstein-Barr virus-transformed B cell lines. J Clin Invest. 1995 Jul;96(1):30-7. Abstract Only.	
	*C88	NARDELLI et al., A chemically defined synthetic vaccine model for HIV-1. J Immunol. 1992 Feb 1;148(3):914-20. Abstract Only.	
	*C89	NICOLA et al., Guidebook to cytokines and their receptors. Sambrook and Tooze publication. 1194; 1-257.	
	*C90	O'BRIEN et al., An immunogenetic analysis of the T-cell recognition of the major house dust mite allergen Der p 2: identification of high- and low-responder HLA-DQ alleles and localization of T-cell epitopes. Immunology. 1995 Oct;86(2):176-82. Abstract Only.	
	*C91	OSTRESH et al., Generation and use of nonsupport-bound peptide and peptidomimetic combinatorial libraries. Methods Enzymol. 1996;267:220-34.	
	*C92	PANINA-BORDIGNON et al., Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur J Immunol. 1989 Dec;19(12):2237-42. Abstract Only.	
	*C93	PERRY et al., Autoreactive T cell specificity in autoimmune hemolytic anemia of the NZB mouse. Eur J Immunol. 1996 Jan;26(1):136-41. Abstract Only.	
	*C94	POWERS et al., Elastase inhibitors for treatment of emphysema - NHLBI workshop summary. US Department of Health and Human Services. 1985; 1097-100.	
	*C95	PROTTI et al., Myasthenia gravis: recognition of a human autoantigen at the molecular level. Immunol Today. 1993 Jul;14(7):363-8. Abstract Only.	
	*C96	REINHOLD et al., Inhibitors of dipeptidyl peptidase IV (DP IV, CD26) induces secretion of transforming growth factor-beta 1 (TGF-beta 1) in stimulated mouse splenocytes and thymocytes. Immunol Lett. 1997 Jun;58(1):29-35.	
	*C97	REINHOLD et al., CD26 mediates the action of HIV-1 Tat protein on DNA synthesis and cytokine production in U937 cells. Immunobiology. 1996 Jan;195(1):119-28.	
	*C98	REYNOLDS et al., T and B epitope determination and analysis of multiple antigenic peptides for the Schistosoma mansoni experimental vaccine triose-phosphate isomerase. J Immunol. 1994 Jan 1;152(1):193-200. Abstract Only.	
	*C99	RINI et al., Crystal structure of a human immunodeficiency virus type 1 neutralizing antibody, 50.1, in complex with its V3 loop peptide antigen. Proc Natl Acad Sci U S A. 1993 Jul 1;90(13):6325-9. Abstract Only.	
	*C100	RITU et al., Construction of synthetic immunogens: use of T- and B-cell epitopes of CS and RESA proteins of Plasmodium falciparum. Vaccine. 1992;10(11):761-5. Abstract Only.	
	*C101	SCHARPE et al., Purified and cell-bound CD26: enzymatic inhibition, antibody binding profile, and expression on T cells in relation to other surface markers. Verh K Acad Geneesk Belg. 1994;56(6):537-59. Abstract Only.	
	*C102	SCHMITZ et al., Potentiation of the immune response in HIV-1+ individuals. J Clin Invest. 1996 Mar 15;97(6):1545-9.	
MB	*C103	SCHON et al., Dipeptidyl peptidase IV in the immune system. Effects of specific enzyme inhibitors on activity of dipeptidyl peptidase IV and proliferation of human lymphocytes. Biol Chem Hoppe Seyler. 1991 May;372(5):305-11.	

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/725,952		ATTY. DOCKET NO.: 10248.70015US01	
				FILING DATE: December 1, 2003		CONFIRMATION NO.: 3968	
				APPLICANT: Bachovchin et al.			
				GROUP ART UNIT: 1631		EXAMINER: Not Yet Assigned	
Sheet	9	of	10				

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
MB	*C104	SCHON et al., The dipeptidyl peptidase IV, a membrane enzyme involved in the proliferation of T lymphocytes. Biomed Biochim Acta. 1985;44(2):K9-15. Abstract Only.	
	*C105	SCHON et al., Dipeptidyl peptidase IV in human T lymphocytes. An approach to the role of a membrane peptidase in the immune system. Biomed Biochim Acta. 1986;45(11-12):1523-8. Abstract Only.	
	*C106	SCHON et al., The role of dipeptidyl peptidase IV in human T lymphocyte activation. Inhibitors and antibodies against dipeptidyl peptidase IV suppress lymphocyte proliferation and immunoglobulin synthesis in vitro. Eur J Immunol. 1987 Dec;17(12):1821-6. Abstract Only.	
	*C107	SEED et al., Making agonists of antagonists. Chem Biol. 1994 Nov;1(3):125-9.	
	*C108	SHIMOJO et al., Identification of the disease-related T cell epitope of ovalbumin and epitope-targeted T cell inactivation in egg allergy. Int Arch Allergy Immunol. 1994 Oct;105(2):155-61. Abstract Only.	
	*C109	SHORT et al., Serum lipoprotein (a) in men with proteinuria due to idiopathic membranous nephropathy. Nephrol Dial Transplant. 1992;7 Suppl 1:109-13. Abstract Only.	
	*C110	SNOW et al., Studies on Proline Boronic Acid Dipeptide Inhibitors of Dipeptidyl Peptidase IV: Identification of a Cyclic Species Containing a B-N Bond. J Am Chem Soc. 1994;116:10860-9.	
	*C111	SONGYANG et al., SH2 domains recognize specific phosphopeptide sequences. Cell. 1993 Mar 12;72(5):767-78.	
	*C112	SUBRAMANYAM et al., Chapter 9: CD26, a T-cell accessory molecule induction of antigen-specific immune-sppression by inactivations of CD26: A clue to the AIDS paradox? in Dipeptidyl Peptidase IV (CD26) in Metabolism and Immune Response, edited by Bernhard Fleischer. 1995: R.G. Landes Company, p155-62.	
	*C113	SUBRAMANYAM et al., Mechanism of HIV-1 Tat induced inhibition of antigen-specific T cell responsiveness. J Immunol. 1993 Mar 15;150(6):2544-53.	
	*C114	SUDMEIER et al., Solution structures of active and inactive forms of the DP IV (CD26) inhibitor Pro-boroPro determined by NMR spectroscopy. Biochemistry. 1994 Oct 18;33(41):12427-38.	
	*C115	TAM et al., Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system. Proc Natl Acad Sci U S A. 1988 Aug;85(15):5409-13.	
	*C116	TANAKA et al., The costimulatory activity of the CD26 antigen requires dipeptidyl peptidase IV enzymatic activity. Proc Natl Acad Sci U S A. 1993 May 15;90(10):4586-90. Abstract Only.	
	*C117	TANAKA et al., Cloning and functional expression of the T cell activation antigen CD26. J Immunol. 1992 Jul 15;149(2):481-6. Erratum in: J Immunol. 1993 Mar 1;150(5):2090. Abstract Only.	
	*C118	THOMPSON et al., Use of peptide aldehydes to generate transition-state analogs of elastase. Biochemistry. 1973 Jan 2;12(1):47-51.	
	*C119	UIBO et al., Characterization of adrenal autoantigens recognized by sera from patients with autoimmune polyglandular syndrome (APS) type I. J Autoimmun. 1994 Jun;7(3):399-411. Abstract Only.	
	*C120	VAN NOORT et al., The small heat-shock protein alpha B-crystallin as candidate autoantigen in multiple sclerosis. Nature. 1995 Jun 29;375(6534):798-801. Abstract Only.	
	*C121	WATSON et al., Continuous proliferation of murine antigen-specific helper T lymphocytes in culture. J Exp Med. 1979 Dec 1;150(6):1510-9. Abstract Only.	
	*C122	WELCH et al., Fluoroolefin containing dipeptide isosteres as inhibitors of dipeptidyl peptidase IV(CD26). Tetrahedron. 1996 January 1;52(1):291-304.	
MB	*C123	WIJENES et al., Monoclonal antibodies (mAb) against gp130 imitating cytokines which use the gp130 for signal transduction. in Special issue: The 9th International Congress of Immunology. San Francisco, California, 23-29 July 1995. Immunol Today. 1995 Jul;16(7):303. Abstract #1794.	

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/725,952		ATTY. DOCKET NO.: 10248.70015US01			
				FILING DATE: December 1, 2003		CONFIRMATION NO.: 3968			
				APPLICANT: Bachovchin et al.					
				GROUP ART UNIT: 1631		EXAMINER: Not Yet Assigned			
Sheet	10	of	10						

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)	
<i>MA</i>	*C124	WYSS-CORAY et al., Use of antibody/peptide constructs of direct antigenic peptides to T cells: evidence for T cell processing and presentation. Cell Immunol. 1992 Jan;139(1):268-73. Abstract Only.		
	*C125	YOSHIMOTO et al., Comparison of inhibitory effects of prolinal-containing peptide derivatives on prolyl endopeptidases from bovine brain and Flavobacterium. J Biochem (Tokyo). 1985 Oct;98(4):975-9.		
	*C126	ZHU et al., T cell epitope mapping of ragweed pollen allergen Ambrosia artemisiifolia (Amb a 5) and Ambrosia trifida (Amb t 5) and the role of free sulfhydryl groups in T cell recognition. J Immunol. 1995 Nov 15;155(10):5064-73. Abstract Only.		
	*C127	ZIMMERMAN et al., A new approach to T-cell activations: natural and synthetic conjugates capable of activating T cells. Vaccine Res. 1996;5(2):91-102.		
<i>MA</i>	*C128	ZIMMERMAN et al., Immunization with peptide heterconjugates primes a T helper cell type 1-associated antibody (IgG2a) response that recognizes the native epitope on the 38-kDa protein of Mycobacterium tuberculosis. Vaccine Res. 1996;5(2):103-18.		


EXAMINER:	DATE CONSIDERED:
<i>[Signature]</i>	<i>10/09/06</i>

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 09/812,528, filed March 20, 2001, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - The Office hereby waives the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b). For all patent applications filed on or before June 30, 2003, copies of cited U.S. patents and patent application publications are still required unless an IDS is filed. Copies of all other patent(s), publication(s), or other information listed must still be provided, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICATION NO.: 10/725,952	ATTY. DOCKET NO.: 10248.70015US01
		FILING DATE: December 1, 2003	CONFIRMATION NO.: 3968
		APPLICANT: Bachovchin et al.	
		GROUP ART UNIT: 1631	EXAMINER: Michael L. Borin
Sheet 1 of 3			



U.S. PATENT DOCUMENTS

Examiner's Initials #	Cite	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
MH	A45	5,939,560		Jenkins et al.	08-17-1999
	A46	6,090,786		Augustyns et al.	07-18-2000
	A47	6,201,132	B1	Jenkins et al.	03-13-2001
	A48	6,265,551		Duke-Cohan et al.	07-24-2001
	A49	6,303,661	B1	Demuth et al.	10-16-2001
	A50	6,500,804		Demuth et al.	12-31-2002
	A51	6,548,481	B1	Demuth et al.	04-15-2003
	A52	6,803,357	B1	Bachovchin et al.	10-12-2004
	A53	6,875,737	B1	Bachovchin	04-05-2005
	A54	6,881,564		Abbott et al.	04-19-2005
	A55	6,890,904	B1	Wallner et al.	05-10-2005
	A56	6,890,905	B2	Demuth et al.	05-10-2005
	A57	6,949,514		Wallner et al.	09-27-2005
	A58	6,946,480		Demuth et al.	09-20-2005
	A59	6,979,697		Wallner	12-27-2005
	A60	2002-0006899	A1	Pospisilik et al.	01-17-2002
	A61	2002-0198242	A1	Demuth et al.	12-26-2002
	A62	2003-0008905	A1	Demuth et al.	01-09-2003
	A63	2003-0119736	A1	Demuth et al.	06-26-2003
	A64	2003-0119750	A1	Demuth et al.	06-26-2003
	A65	2003-0130199	A1	von Hoersten et al.	07-10-2003
	A66	2003-0134802	A1	Demuth et al.	07-17-2003
	A67	2003-0135023	A1	Demuth et al.	07-17-2003
	A68	2003-0153509	A1	Bachovchin et al.	08-14-2003
	A69	2003-0162820	A1	Demuth et al.	08-28-2003
	A70	2003-0176357	A1	Pospisilik et al.	09-18-2003
	A71	2004-0053369	A1	Abbott et al.	03-18-2004
	A72	2004-0152192	A1	Bachovchin et al.	08-05-2004
	A73	2004-0167191	A1	Demuth et al.	08-26-2004
	A74	2004-0176307	A1	Bachovchin et al.	09-09-2004
	A75	2004-0191826	A1	Abbott et al.	09-30-2004
	A76	2004-0229820	A1	Bachovchin et al.	11-18-2004
MH	A77	2004-0229848	A1	Demuth et al.	11-18-2004

EXAMINER:	DATE CONSIDERED:
-----------	------------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/725,952		ATTY. DOCKET NO.: 10248.70015US01			
				FILING DATE: December 1, 2003		CONFIRMATION NO.: 3968			
				APPLICANT: Bachovchin et al.					
				GROUP ART UNIT: 1631		EXAMINER: Michael L. Borin			
Sheet	2	of	3						


mn	A78	2005-0008644	A1	Huber et al.	01-13-2005
	A79	2005-0043299	A1	Evans et al.	02-24-2005
	A80	2005-0084490	A1	Adams et al.	04-21-2005
	A81	2005-0107308	A1	Pospisilik et al.	05-19-2005
	A82	2005-0171025	A1	Von Hoersten et al.	08-04-2005
	A83	2005-0202027	A1	Bachovchin	09-15-2005
	A84	2005-0203027	A1	Bachovchin et al.	09-15-2005
	A85	2005-0209249	A1	Akritopoulou-Zanze et al.	09-22-2005
	A86	2005-0215603	A1	Akritopoulou-Zanze et al.	09-29-2005
	A87	2005-0215784	A1	Madar et al.	09-29-2005
	A88	2005-0272703	A1	Wallner et al.	12-08-2005
	A89	2006-0052310	A1	Wallner et al.	03-09-2006
	A90	2006-0063719	A1	Jesson et al.	03-23-2006
mn	A91	2006-0094693	A1	Aziz et al.	05-04-2006

FOREIGN PATENT DOCUMENTS

Examiner's Initials #	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
mn	B45	WO	99/28474	A2	The Government of the United States of America	06-10-1999	
	B46	WO	01/89569	A1	Institut für Medizintechnologie Magdeburg GmbH Imtm	11-29-2001	Y-Abstract
mn	B47	WO	2005/071073	A1	Point Therapeutics, Inc.	08-04-2005	

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
mn	C131	BORLOO et al., Dipeptidyl peptidase IV: development, design, synthesis and biological evaluation of inhibitors. Verh K Acad Geneesk Belg. 1994;56(1):57-88.	
	C132	BRISTOL et al., Thymocyte costimulating antigen is CD26 (dipeptidyl-peptidase IV). Costimulation of granulocyte, macrophage, and T lineage cell proliferation via CD26. J Immunol. 1992 Jul 15;149(2):367-72.	
	C133	BRISTOL et al., Inhibition of CD26 enzyme activity with pro-boropro stimulates rat granulocyte/macrophage colony formation and thymocyte proliferation in vitro. Blood. 1995 Jun 15;85(12):3602-9.	
mn	C134	CHIRAVURI et al., A novel apoptotic pathway in quiescent lymphocytes identified by inhibition of a post-proline cleaving aminodipeptidase: a candidate target protease, quiescent cell proline dipeptidase. J Immunol. 1999 Sep 15;163(6):3092-9.	

EXAMINER:	DATE CONSIDERED:
	10/04/06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/725,952	ATTY. DOCKET NO.: 10248.70015US01
				FILING DATE: December 1, 2003	CONFIRMATION NO.: 3968
				APPLICANT: Bachovchin et al.	
				GROUP ART UNIT: 1631	EXAMINER: Michael L. Borin
Sheet	3	of	3		

<i>mm</i>	C135	CHRISTOPHERSON et al., Modulation of hematopoietic stem cell homing and engraftment by CD26. Science. 2004 Aug 13;305(5686):1000-3.	
	C136	COUTTS et al., Two efficient methods for the cleavage of pinanediol boronate esters yielding the free boronic acids. Tetrahedron Letts. 1994;35(29):5109-12.	
	C137	FLEISHER et al., Triggering of cytotoxic T lymphocytes and NK cells via the Tp103 pathway is dependent on the expression of the T cell receptor/CD3 complex. J Immunol. 1988 Aug 15;141(4):1103-7. Abstract Only.	
	C138	FLENTKE et al., Inhibition of dipeptidyl aminopeptidase IV (DP-IV) by Xaa-boroPro dipeptides and use of these inhibitors to examine the role of DP-IV in T-cell function. Proc Natl Acad Sci U S A. 1991 Feb 15;88(4):1556-9.	
	C139	HOFFMANN et al., Dipeptidyl peptidase IV (CD 26) and aminopeptidase N (CD 13) catalyzed hydrolysis of cytokines and peptides with N-terminal cytokine sequences. FEBS Lett. 1993 Dec 20;336(1):61-4.	
	C140	LOKSHINA et al., Proteolytic enzymes in human leukemic lymphoid cells. III. Aminopeptidases, angiotensin-converting enzyme, and its inhibitor in cells of different immunological phenotype. Biochemistry (Mosc). 1999 Apr;64(4):448-55. Abstract Only.	
	C141	MITTRUCKER et al., The cytoplasmic tail of the T cell receptor zeta chain is required for signaling via CD26. Eur J Immunol. 1995 Jan;25(1):295-7. Abstract Only.	
<i>mm</i>	C142	ROSENBLUM et al., Prolyl peptidases: a serine protease subfamily with high potential for drug discovery. Curr Opin Chem Biol. 2003 Aug;7(4):496-504.	

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

EXAMINER:	DATE CONSIDERED:
<i>[Signature]</i>	<i>10/24/06</i>

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.